Severe metabolic acidemia, commonly defined as arterial pH ≤7.20, is associated with several physiologic consequences including impaired cardiac contractility, arrhythmias, pulmonary vasoconstriction, systemic vasodilation, altered kidney blood flow, cerebral edema, and diaphragmatic dysfunction. In critically ill patients, common contributors include hyperchloremic acidosis, lactate accumulation, and endogenous anion accumulation during acute kidney injury.

The role of intravenous sodium bicarbonate in severe metabolic acidemia remains controversial. In the prior BICARICU-1 trial, sodium bicarbonate did not significantly improve the overall composite primary outcome in an unselected severe metabolic acidemia population. However, a prespecified subgroup of patients with moderate-to-severe acute kidney injury appeared to have lower day 28 mortality and less kidney replacement therapy use with bicarbonate therapy.

BICARICU-2 was designed to specifically evaluate whether sodium bicarbonate improves outcomes in critically ill patients with both severe metabolic acidemia and moderate-to-severe acute kidney injury.

Study Relevance

This study is clinically important because sodium bicarbonate is commonly used in ICU patients with severe acidemia, but evidence supporting mortality benefit is limited. This trial directly addresses a high-risk ICU population: patients with severe metabolic acidemia plus KDIGO stage 2 or 3 acute kidney injury. The results help clarify whether bicarbonate should be used to improve survival, reduce kidney replacement therapy, or serve mainly as a temporizing measure.

General Study Overview

Trial Design: Multicenter, randomized, open-label clinical trial with 2 parallel groups.

Objective: To determine whether intravenous sodium bicarbonate infusion improves day 90 all-cause mortality in critically ill adults with severe metabolic acidemia and moderate-to-severe acute kidney injury.

Funding: Funded by the French Ministry of Health through the Programme Hospitalier de Recherche Clinique National.

Study Outcomes

Day 90 all-cause mortality was not significantly different between groups.

Subscribe now

Read more

For more than a decade, clinicians treating acute venous thromboembolism (VTE) have had two reliable direct oral anticoagulants to choose from: apixaban and rivaroxaban. Both work. Both sit at the top of major guideline recommendations. And until very recently, the choice between them often came down to clinician preference, insurance coverage, or habit.

The COBRRA trial, published in the New England Journal of Medicine in March 2026, finally puts the two drugs in the same ring. The verdict is decisive: apixaban produces significantly less bleeding, and the difference is not subtle.

Both apixaban and rivaroxaban earned their FDA approvals by going up against vitamin K antagonists like warfarin — not against each other. In the AMPLIFY trial, apixaban roughly halved the rate of clinically relevant bleeding compared with warfarin. In the EINSTEIN program, rivaroxaban produced about the same amount of bleeding as warfarin.

That apparent gap hinted that apixaban might be the safer choice. But cross-trial comparisons are notoriously unreliable — patient populations differ, bleeding adjudication differs, background care differs. You cannot simply line up two trials’ bleeding rates and crown a winner. COBRRA was designed to do what those indirect comparisons could not: randomize patients directly between the two drugs and see what happens.

General Study Overview:

• Trial Design: International, multicenter, pragmatic, prospective, randomized, open-label, blinded end-point (PROBE) trial. 1:1 randomization, stratified by renal function, antiplatelet use, and site.

• Objective: To determine whether apixaban is superior to rivaroxaban with respect to safety (clinically relevant bleeding) in patients with acute symptomatic VTE treated for 3 months.

• Funding: Canadian Institutes of Health Research; Medical Research Future Fund (Australia); Royal College of Surgeons in Ireland; International Network of VTE Clinical Research Networks.

Methods:

Inclusion Criteria:

• Adults ≥18 years of age

• Symptomatic acute proximal lower-limb DVT, OR segmental or more proximal pulmonary embolism

Exclusion Criteria:

• Therapeutic anticoagulation >72 hours immediately before enrollment

• CrCl <30 mL/min (Cockcroft-Gault)

• Any contraindication to apixaban or rivaroxaban (active bleeding, etc.)

• Active cancer

• Use of contraindicated interacting medications

• Another indication for long-term anticoagulation (e.g., atrial fibrillation)

Interventions:

• 1:1 randomization, stratified by renal function (CrCl <50 vs ≥50 mL/min), planned antiplatelet use, and site

• Apixaban: 10 mg PO BID × 7 days, then 5 mg PO BID for the remainder of 3 months

• Rivaroxaban: 15 mg PO BID × 21 days, then 20 mg PO daily for the remainder of 3 months

Primary Endpoints:

1. Clinically relevant bleeding (composite) over 3 months, per ISTH definitions:

   1. Major bleeding — overt bleeding in a critical site, ≥2 g/dL hemoglobin drop, ≥2 units PRBC transfusion, or bleeding contributing to death

   2. Clinically relevant nonmajor bleeding (CRNMB) — bleeding not meeting major criteria but requiring medical intervention, hospitalization/increased level of care, or face-to-face evaluation

Secondary Endpoints:

• Individual components of the primary outcome (major bleeding; CRNMB)

• Recurrent symptomatic VTE (recurrent DVT or PE)

• Death from bleeding

• Death from recurrent VTE

• Death from any cause

• Medication adherence at each follow-up visit

Statistical Analyses:

• Designed for 80% power, two-sided α = 0.05, to detect a 33% relative risk reduction (assumed 5.4% apixaban vs. 8.1% rivaroxaban event rate)

• Intention-to-treat (ITT) analysis

Results:

Participant flow:

• Enrollment Dec 13, 2017 – Jan 23, 2025 (≈7 years) at 32 centers in Canada, Australia, and Ireland

• 9,753 patients screened → 2,760 randomized (1,370 apixaban; 1,390 rivaroxaban)

  60 patients (2.2%) excluded post-randomization

• ITT analysis: 1,345 apixaban; 1,355 rivaroxaban

• Loss to follow-up: 13 (1.0%) apixaban; 15 (1.1%) rivaroxaban — better than assumed 2%

Baseline Characteristics:

• Mean age 58.3 years

• Mean weight 85.5 kg; mean BMI ~29

• 43.5% female

• 77.3% unprovoked VTE

Study Outcomes:

1. Primary outcome (CRB): 3.3% (44/1,345) with apixaban vs. 7.1% (96/1,355) with rivaroxaban; RR 0.46 (95% CI 0.33–0.65), P<0.001. Adjusted marginal RR 0.45 (95% CI 0.32–0.64).

   1. ARR = 3.8%; NNT ≈ 26 patients treated with apixaban (vs. rivaroxaban) for 3 months to prevent one episode of clinically relevant bleeding.

2. Recurrent VTE: 1.1% vs. 1.0% (RR 1.08; 95% CI 0.52–2.23). No signal of efficacy trade-off, but the trial was not powered to detect non-inferiority for thrombotic outcomes

3. Medication adherence: 65.7% apixaban vs. 75.1% rivaroxaban — lower adherence in the apixaban arm strengthens the bleeding-benefit signal (apixaban produced less bleeding despite less consistent dosing).

4. Safety: Non-bleeding, non-VTE serious adverse events: 2.7% apixaban vs. 2.2% rivaroxaban (similar). No fatal bleeding in either arm.

Limitations:

• Open-label design

• Short follow-up (3 months)

• No adjustment for multiplicity

• Underpowered for efficacy

• Excluded populations

• Limited diversity

• Long enrollment period

• Adherence imbalance

• Bleeding definition limitations

Conclusion:

For the typical outpatient with acute symptomatic proximal DVT or PE — preserved renal function, no active cancer, weight under 120 kg, no atrial fibrillation — COBRRA delivers the first high-quality randomized evidence to prefer one DOAC over the other. Apixaban produces meaningfully less bleeding without giving up any apparent efficacy. The result is large, statistically robust, mechanistically plausible, and consistent with what prior cross-trial comparisons had only hinted at.

Disclaimer: The content provided on this Substack is for informational, educational, and entertainment purposes only. All journal article summaries, reviews, and analyses are based on publicly available research and do not contain any original copyrighted materials. The summaries do not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any medical decisions. The author(s) of this Substack are not responsible for any actions taken based on the information provided. Any referenced studies, images, or quotes belong to their respective copyright holders, and their inclusion here is solely for fair-use educational purposes.

Prediabetes is common and is characterized by dysglycemia and insulin resistance, which are linked to early vascular dysfunction and increased cardiovascular risk. Dietary patterns emphasizing fruits and plant foods are associated with better cardiometabolic health; avocados and mangos may provide complementary fiber, micronutrients, and unsaturated fats.

General Study Overview:

• Trial Design: Randomized, single-blinded, 2-arm, partially controlled, 8-week parallel diet intervention

• Objective: To determine whether increasing total fruit intake and dietary diversity by adding daily avocado and mango for 8 weeks improves endothelial function and other cardiometabolic markers in adults with prediabetes.

• Funding: Hass Avocado Board and the National Mango Board

Preview of Results:

Read more

Empirical use of antipseudomonal β-lactam antibiotics like cefepime and piperacillin-tazobactam is standard for hospitalized patients with suspected serious infections. However, observational data suggest possible safety concerns: cefepime may be neurotoxic (delirium/coma), and piperacillin-tazobactam has been associated with acute kidney injury (AKI), particularly when used with vancomycin. Prior to this trial, no randomized clinical trial had directly compared these two antibiotics to assess these safety concerns.

Given the widespread use of both antibiotics, especially in critically ill patients, this study provides valuable randomized evidence regarding their comparative safety profiles—critical for informing clinical decisions in the empiric treatment of serious infections.

Subscribe now

Read more

Respiratory syncytial virus (RSV) is a leading cause of pediatric lower respiratory tract disease, responsible for ~33 million LRIs and ~101,400 deaths globally in children <5 years (2019 estimates). Current strategies—maternal vaccination and monoclonal antibody prophylaxis—primarily protect the first 6 months of life, leaving an unmet need for active, durable immunization as >50% of RSV-related deaths and ~80% of LRIs occur at ≥6 months of age. Historical vaccine efforts were complicated by enhanced respiratory disease after formalin-inactivated RSV vaccines, and more recent infant mRNA candidates showed imbalances in severe LRI. In contrast, live-attenuated, intranasal vaccines (LAVs) mimic natural infection, induce mucosal and systemic immunity, and to date have not been associated with vaccine-enhanced disease, making them attractive for infants and toddlers. The candidate tested here (RSV/ΔNS2/Δ1313/I1314L, “RSVt”) deletes the interferon-antagonist NS2 gene and incorporates stabilizing L-protein mutations; its genome matches a previously studied NIH construct that showed acceptable safety and immunogenicity in RSV-seronegative children.

Subscribe now

Read more

The 2022 ACC/AHA guidelines for Heart Failure with Reduced Ejection Fraction (HFrEF) recommend the use of steroidal mineralocorticoid receptor antagonists (MRA’s), such as spironolactone and eplerenone (along with others), due to mortality benefit. These same guidelines state MRA’s and other HFrEF guideline directed medical therapies may be considered to reduce risk of hospitalization and mortality in Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) in patients who are symptomatic and have a Left Ventricular Ejection Fraction (LVEF) on the lower end of the spectrum (41% - 49%). Regardless of LVEF, Finerenone, a non-steroidal MRA, has not been mentioned within the guidelines for the treatment of heart failure patients. Being non-steroidal, Finerenone exhibits more targeted action, particularly on the cardiovascular and renal systems which has led to its FDA approval for chronic kidney disease (CKD) in patients with type 2 diabetes (T2DM) after the FIDELIO-DKD trial in 2021. The relevance of the following study is how Finerenone may be an additional option to the existing steroidal MRA’s and provide similar clinical benefit (morbidity and mortality) in patients with HFmrEF and HFpEF with more targeted activity.

Subscribe now

Read more

Type 2 diabetes is progressive, and basal insulin initiation is recommended when non-insulin therapies fail to maintain glycemic control. However, daily injections can be a barrier due to perceived complexity, fear of hypoglycemia, weight gain, and treatment inertia. Once-weekly insulin formulations aim to reduce injection burden, potentially improving adherence and earlier initiation. Insulin efsitora alfa is a novel once-weekly basal insulin with a flat PK profile and long half-life. Phase 1/2 data suggested similar efficacy/safety vs daily basal insulin. QWINT-2 is part of a 5-trial phase 3 program evaluating efsitora. This trial compares efsitora vs insulin degludec in insulin-naïve adults with T2DM.

Subscribe now

Read more

Atrial fibrillation (AF) significantly increases the risk of stroke. Current anticoagulant strategies, including direct oral anticoagulants (DOACs) like apixaban, effectively reduce thromboembolic risk but are associated with bleeding, especially gastrointestinal and intracranial bleeding. Asundexian is an oral, selective inhibitor of activated factor XI (FXIa), designed to reduce thrombosis with potentially less bleeding risk than conventional anticoagulants that target thrombin or factor Xa.

OCEANIC-AF explores whether asundexian, a novel anticoagulant with a unique mechanism targeting FXIa, is safer than the established DOAC apixaban in preventing stroke in patients with AF. Reducing bleeding while maintaining efficacy could represent a major advance in anticoagulation therapy.

Subscribe now

Read more

Percutaneous coronary intervention (PCI) is commonly performed in patients with coronary artery disease, requiring rapid and effective platelet inhibition to prevent thrombotic complications. Oral P2Y₁₂ inhibitors like clopidogrel are often used, but they exhibit delayed onset and variable absorption, especially in emergent settings. Cangrelor is an intravenous, reversible, direct-acting P2Y₁₂ inhibitor with immediate onset and offset, potentially overcoming limitations of oral agents.

Previous trials (CHAMPION PCI and PLATFORM) failed to demonstrate benefit due to suboptimal trial design or choice of control groups. CHAMPION PHOENIX aimed to address these issues by comparing cangrelor to clopidogrel with robust methodology and a focus on clinically relevant ischemic outcomes.

The study addresses a critical gap in periprocedural antiplatelet management, especially in settings where rapid, potent, and short-lived platelet inhibition is desirable. Findings from this trial may influence guideline recommendations and clinical practice, particularly in acute coronary syndrome and elective PCI populations.

General Study Overview:

• Trial Design: Phase 3, randomized, double-blind, double-dummy, active-controlled trial.

• Objective: To evaluate whether cangrelor reduces ischemic complications during PCI compared to clopidogrel.

• Funding: Supported by The Medicines Company.

Summary:

Cangrelor is a valuable antiplatelet agent in PCI, particularly for patients not pretreated with oral P2Y₁₂ inhibitors or in whom rapid onset and offset are critical. While it did not increase major bleeding significantly, cost and specific clinical scenarios will guide its adoption. Its use may be especially beneficial in high-risk PCI or in ACS patients undergoing urgent intervention.

Subscribe now

Read more

Antiplatelet medications are commonly prescribed to patients to prevent cardiac or cerebrovascular events. The downside to these agents is they can increase a patients risk for bruising or bleeding with the most significant being intracranial hemorrhage (ICH). Although the evidence is not robust, antiplatelet agents have been associated with hematoma expansion, higher mortality, and decreased functional outcomes. Current literature for management of patients with ICH associated with antiplatelet medications is minimal and most data is based on aspirin and not on other P2Y12 inhibitors or dual antiplatelet therapy (DAPT).

Current guidelines from Society of Critical Care Medicine (SCCM) and Neurocritical Care Society (NCS) recommend using a single dose of desmopressin (DDAVP) to potentially prevent hematoma expansion.

It is unclear whether DDAVP is actually beneficial when used for this indication as the current provided literature is conflicting. This study aims to examine the safety and efficacy of DDAVP in patients with antiplatelet-associated ICH.

General Study Overview:

• Trial Design: Multi-center, retrospective, cohort study, conducted across three medical institutions

• Objective: Examine the safety and efficacy of DDAVP in patients with antiplatelet-associated ICH

• Funding: Not explicitly stated

Summary:

In patients with antiplatelet-associated ICH, DDAVP did not result in any significant difference in hematoma expansion when compared to no those that did not receive DDAVP.

Subscribe now

Read more

Artificial Intelligence (AI), specifically large language models (LLM's), have shown potential to augment medical practice. Prior evaluations of LLM’s have used simulated exams or open-source datasets, but lacked real world physician performance comparisons. This study uniquely compares GPT-3.5 and GPT-4 to 849 resident physicians taking official Israeli board exams in five medical specialties.

Importantly, this benchmark exclusively evaluates ChatGPT models (GPT-3.5 and GPT-4) and does not include newer or competing platforms such as OpenEvidence (affiliated with NEJM), DeepSeek, Gemini (Google), Microsoft Copilot, Perplexity AI, or Claude by Anthropic. These alternative models are increasingly gaining traction in medical and academic environments, and their comparative performance on official board exams remains unexplored.

With growing interest in integrating AI into clinical workflows, understanding whether AI models can match or exceed physician performance is crucial. This study establishes a foundation to evaluate the readiness of LLM’s in medicine and clinical decision making.

General Study Overview:

• Trial design: Retrospective analysis of physician performance on the 2022 medical board certification exam across 5 medical specialties. Data of performance was obtained from the Israeli Medical Association.

• Objective: Assess the performance of generative pretrained transformer (GPT) 3.5 and 4 on official board exams compared with the performance of practicing physicians across 5 specialties.

• Funding: Not explicitly mentioned.

Summary:

This study demonstrates the rapid and substantial improvements in large language models, with each new iteration showing significant gains in performance over a short time frame. As AI capabilities grow exponentially, we are nearing a threshold where the ethical question becomes “Why should we NOT use these tools”. However, risks such as training bias, prompt sensitivity, and hallucinations are real and must be acknowledged. To truly benefit from AI in medicine, healthcare professionals should be trained to use these models in combination with their clinical training to enhance patient centered care.

Subscribe now

Read more

Direct oral anticoagulants (DOACs) are widely used for stroke prevention in patients with atrial fibrillation (AF) due to their efficacy in reducing risk of ischemic stroke while posing a relatively low risk of intracranial hemorrhage (ICH) compared to other agents, such as warfarin.

The timing of anticoagulation after an acute ischemic stroke remains a challenge. Early initiation of DOACs may reduce risk of recurrent stroke but there are concerns about hemorrhagic transformation, especially in patients with larger infarcts or severe strokes. Current practices often vary based on stroke severity due to the lack of robust, high-quality evidence to guide the appropriate timing of anticoagulation in this setting.

The TIMING and ELAN trials from 2022 and 2023 have explored this question and provided some evidence to suggest early initiation of DOACs may be non-inferior to delayed initiation. However, gaps remain, especially in patients with moderate to severe strokes when it comes to safety of early anticoagulation.

In the absence of high-quality evidence to support timing of DOACs after acute ischemic stroke in atrial fibrillation the OPTIMAS trial hopes to establish safety and efficacy of early anticoagulation in this population.

General Study Overview

• Trial design: Phase 4, multicenter, parallel-group, randomized, controlled trial with an open-label intervention, blinded endpoint adjudication, and hierarchical non-inferiority-superiority gatekeeper design

• Objective: Aims to establish safety and efficacy of early DOAC initiation in patients with acute ischemic stroke associated with AF

• Funding: British Heart Foundation

Summary:

Based on the findings of this study, in combination with ELAN and TIMING trials, early initiation of DOACs within the first 4 days post-acute ischemic stroke appears to be non-inferior to delayed DOAC initiation. These results may offer a favorable balance between minimizing risk of recurrent ischemic events and maintaining a low risk of hemorrhagic complications. While further research may refine the exact timing and potentially identify subgroups that would benefit most, the results from this study provide compelling evidence for the safety and efficacy of early DOAC initiation.

Read more

Ticagrelor is a reversible oral P2Y12 platelet inhibitor widely used for the prevention of ischemic events in patients with acute coronary syndrome (ACS), myocardial infarction (MI), and high risk coronary artery disease (CAD). Ticagrelor is unique in its mechanism compared to the alternative irreversible P2Y12 inhibitors:

• Clopidogrel

• Prasugrel

The unique reversible mechanism renders platelet transfusions, essentially, worthless for patients who may need to undergo surgery and may be at an increased risk of bleeding.

Bentracimab, is a monoclonal antibody fragment that binds ticagrelor and its active metabolites, providing a rapid and sustained reversal of its antiplatelet effects.

Given the lack of reversal agents for ticagrelor or other P2Y12 inhibitors, the REVERSE-IT trial is important in determining the safety and efficacy of Bentracimab in mitigating bleeding risks while preserving surgical outcomes.

General Study Overview:

• Trial design: Multicenter, single arm, open-label

• Objective: To assess the efficacy and safety of Bentracimab for ticagrelor reversal in patients undergoing urgent surgery or experiencing major bleeding

• Funding: PhaseBio Pharmaceuticals, Inc

Summary:

The results of this interim analysis show a statistically significant inhibition of platelet reactivity with Bentracimab which may provide insight to a potential ticagrelor reversal agent. Although, due to its various limitations, clinical significance should be thoroughly reviewed prior to any discussions regarding formulary integration.

Read more

Each week, I’ll be sharing clear, concise, and high-value breakdowns of the most important medical literature – the kind that shapes practice, sparks debate, and too often goes misunderstood or unread.

What You Can Expect

🧠 Journal Club Reviews

Every post will focus on a single trial or article. I’ll walk through the methodology, limitations, outcomes, and—most importantly—how it should (or should not) impact your clinical decisions.

📌 Clinical Relevance

My goal isn’t to summarize for the sake of summary. Every article review will answer one question: “What should I do differently on Monday?” You’ll walk away with key takeaways grounded in both evidence and frontline experience.

✍️ Occasional Essays and Commentary

Beyond journal clubs, I’ll share thoughts on broader trends in healthcare, pharmacy, medical practice, therapeutics, and the subtle (or not-so-subtle) ways the system pushes us away from high-quality, patient-centered care.

Who This Is For

• Pharmacists who want to stay sharp without sorting through piles of papers.

• Residents and students looking for an edge in journal clubs or clinical discussions.

• Clinicians who value critical thinking, not just guideline regurgitation.

• And anyone who believes that understanding medical literature should be both rigorous and accessible.

This project is about cutting through noise, focusing on what matters, and delivering high-quality insight in a way that respects your time and intelligence.

Thank you again for being part of this.
Let’s get started.

— DirtyDose